JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hicks, R. J.
Right arrow Articles by Ball, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hicks, R. J.
Right arrow Articles by Ball, D. L.
Journal of Nuclear Medicine Vol. 42 No. 11 1596-1604
© 2001 by Society of Nuclear Medicine

Clinical Investigations

18F-FDG PET Provides High-Impact and Powerful Prognostic Stratification in Staging Newly Diagnosed Non–Small Cell Lung Cancer

Rodney J. Hicks, Victor Kalff, Michael P. MacManus, Robert E. Ware, Annette Hogg, Allan F. McKenzie, Jane P. Matthews and David L. Ball

Department of Diagnostic Imaging, Division of Radiation Oncology, and Pratt Foundation Statistical Centre, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia

Survival of lung cancer patients remains poor despite increasingly aggressive treatment. Conventional staging has well-described limitations. 18F-FDG PET has been shown to stage lung cancer more accurately than does CT scanning, but the impact on patient treatment and outcome is poorly defined. This study evaluated this impact in routine clinical practice within a tertiary oncology facility. Methods: For 153 consecutive patients with newly diagnosed non–small cell lung cancer, the treatment plan based on conventional staging methods was compared with the treatment plan based on incorporation of PET findings. Survival was analyzed using the Cox proportional hazards regression model. Results: For broad groupings of stage, 10% of cases were downstaged and 33% upstaged by PET. When assessable, the PET stage was confirmed in 89% of patients. PET had a high impact on 54 patients (35%), including 34 whose therapy was changed from curative to palliative, 6 whose therapy was changed from palliative to curative, and 14 whose treatment modality was changed but not the treatment intent. For 39 patients (25%), a previously selected therapy was altered because of the PET findings. The Cox model indicated that the pre-PET stage was significantly associated with survival (P = 0.013) but that the post-PET stage provided much stronger prognostic stratification (P < 0.0001) and remained significant after adjustment for treatment delivered. Conclusion: Staging that incorporated PET provided a more accurate prognostic stratification than did staging based on conventional investigations. Further, the additional information provided by PET significantly and appropriately changed management in the majority of patients.

Key Words: FDG • PET • lung cancer • staging • prognosis • impact




This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
D. E. Maziak, G. E. Darling, R. I. Inculet, K. Y. Gulenchyn, A. A. Driedger, Y. C. Ung, J. D. Miller, C.-S. Gu, K. J. Cline, W. K. Evans, et al.
Positron Emission Tomography in Staging Early Lung Cancer: A Randomized Trial
Ann Intern Med, August 18, 2009; 151(4): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. A. Silvestri, M. K. Gould, M. L. Margolis, L. T. Tanoue, D. McCrory, E. Toloza, and F. Detterbeck
Noninvasive Staging of Non-small Cell Lung Cancer: ACCP Evidenced-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 178S - 201S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard
Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer
J. Nucl. Med., April 1, 2006; 47(4): 559 - 565.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Guo, K. Higashi, Y. Ueda, M. Oguchi, T. Takegami, H. Toga, T. Sakuma, H. Yokota, S. Katsuda, H. Tonami, et al.
Microvessel Density: Correlation with 18F-FDG Uptake and Prognostic Impact in Lung Adenocarcinomas
J. Nucl. Med., March 1, 2006; 47(3): 419 - 425.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Lardinois, W. Weder, M. Roudas, G. K. von Schulthess, M. Tutic, H. Moch, R. A. Stahel, and H. C. Steinert
Etiology of Solitary Extrapulmonary Positron Emission Tomography and Computed Tomography Findings in Patients With Lung Cancer
J. Clin. Oncol., October 1, 2005; 23(28): 6846 - 6853.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Schrevens, N. Lorent, C. Dooms, and J. Vansteenkiste
The Role of PET Scan in Diagnosis, Staging, and Management of Non-Small Cell Lung Cancer
Oncologist, November 1, 2004; 9(6): 633 - 643.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Glatting, and S. N. Reske
Quantification of 18F-FDG Uptake in Non-Small Cell Lung Cancer: A Feasible Prognostic Marker?
J. Nucl. Med., August 1, 2004; 45(8): 1274 - 1276.
[Full Text] [PDF]

Home page
 JNMHome page
J. Guo, K. Higashi, H. Yokota, Y. Nagao, Y. Ueda, Y. Kodama, M. Oguchi, S. Taki, H. Tonami, and I. Yamamoto
In Vitro Proton Magnetic Resonance Spectroscopic Lactate and Choline Measurements, 18F-FDG Uptake, and Prognosis in Patients with Lung Adenocarcinoma
J. Nucl. Med., August 1, 2004; 45(8): 1334 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
P. S. Oturai, J. Mortensen, H. Enevoldsen, A. Eigtved, V. Backer, K. P. Olesen, H. W. Nielsen, H. Hansen, P. Stentoft, and L. Friberg
{gamma}-Camera 18F-FDG PET in Diagnosis and Staging of Patients Presenting with Suspected Lung Cancer and Comparison with Dedicated PET
J. Nucl. Med., August 1, 2004; 45(8): 1351 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. C. Detterbeck, S. Falen, M. P. Rivera, J. S. Halle, and M. A. Socinski
Seeking a Home for a PET, Part 2: Defining the Appropriate Place for Positron Emission Tomography Imaging in the Staging of Patients With Suspected Lung Cancer
Chest, June 1, 2004; 125(6): 2300 - 2308.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
G. Halter, A. K. Buck, H. Schirrmeister, I. Wurziger, F. Liewald, G. Glatting, B. Neumaier, L. Sunder-Plassmann, S. N. Reske, and M. Hetzel
[18F] 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1093 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JNMHome page
J. D. Bradley, C. A. Perez, F. Dehdashti, and B. A. Siegel
Implementing Biologic Target Volumes in Radiation Treatment Planning for Non-Small Cell Lung Cancer
J. Nucl. Med., January 1, 2004; 45(90010): 96S - 101.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, and M. Hetzel
Imaging Proliferation in Lung Tumors with PET: 18F-FLT Versus 18F-FDG
J. Nucl. Med., September 1, 2003; 44(9): 1426 - 1431.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R Booton, M Jones, and N Thatcher
Lung cancer * 7: Management of lung cancer in elderly patients
Thorax, August 1, 2003; 58(8): 711 - 720.
[Full Text] [PDF]

Home page
 JNMHome page
H. Stevens, P. F.A. Bakker, N. J.J. Schlosser, P. P. van Rijk, and J. M.H. de Klerk
Use of a Dual-Head Coincidence Camera and 18F-FDG for Detection and Nodal Staging of Non-Small Cell Lung Cancer: Accuracy as Determined by 2 Independent Observers
J. Nucl. Med., March 1, 2003; 44(3): 336 - 340.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
R. J. Hicks and M. P. Mac Manus
18F-FDG PET in Candidates for Radiation Therapy: Is It Important and How Do We Validate Its Impact?
J. Nucl. Med., January 1, 2003; 44(1): 30 - 32.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. G. Spiro and J. C. Porter
Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment
Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Buck, H. Schirrmeister, M. Hetzel, M. von der Heide, G. Halter, G. Glatting, T. Mattfeldt, F. Liewald, S. N. Reske, and B. Neumaier
3-Deoxy-3-[18F]Fluorothymidine-Positron Emission Tomography for Noninvasive Assessment of Proliferation in Pulmonary Nodules
Cancer Res., June 1, 2002; 62(12): 3331 - 3334.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.